Roy van der Meel

11.3k total citations · 9 hit papers
51 papers, 7.9k citations indexed

About

Roy van der Meel is a scholar working on Molecular Biology, Biomaterials and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Roy van der Meel has authored 51 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 19 papers in Biomaterials and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Roy van der Meel's work include RNA Interference and Gene Delivery (27 papers), Nanoparticle-Based Drug Delivery (18 papers) and Advanced biosensing and bioanalysis techniques (15 papers). Roy van der Meel is often cited by papers focused on RNA Interference and Gene Delivery (27 papers), Nanoparticle-Based Drug Delivery (18 papers) and Advanced biosensing and bioanalysis techniques (15 papers). Roy van der Meel collaborates with scholars based in Netherlands, Canada and Germany. Roy van der Meel's co-authors include Pieter R. Cullis, Jayesh A. Kulkarni, Dominik Witzigmann, Sam Chen, Raymond M. Schiffelers, Twan Lammers, Willem J. M. Mulder, Yang Shi, Fabian Kießling and Pieter Vader and has published in prestigious journals such as Nature Materials, Accounts of Chemical Research and Blood.

In The Last Decade

Roy van der Meel

51 papers receiving 7.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

2019 1.2k citations Akin Akinc, Martin A. Maier et al. Nature Nanotechnology profile →
Smart cancer nanomedicine

2019 946 citations Roy van der Meel, Einar Sulheim et al. Nature Nanotechnology profile →
The current landscape of nucleic acid therapeutics

2021 934 citations Jayesh A. Kulkarni, Dominik Witzigmann et al. Nature Nanotechnology profile →
PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time

2016 506 citations Sander A. A. Kooijmans, Lies A. L. Fliervoet et al. Journal of Controlled Release profile →
On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA

2018 457 citations Jayesh A. Kulkarni, Sam Chen et al. profile →
Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility

2018 411 citations Jayesh A. Kulkarni, Pieter R. Cullis et al. profile →
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics

2019 376 citations Jayesh A. Kulkarni, Dominik Witzigmann et al. profile →
Lipid nanoparticle technology for therapeutic gene regulation in the liver

2020 273 citations Dominik Witzigmann, Jayesh A. Kulkarni et al. profile →
Engineering cytokine therapeutics

2023 132 citations Jeroen Deckers, Anne de Dreu et al. Nature Reviews Bioengineering profile →

Peers

Countries citing papers authored by Roy van der Meel

Since Specialization

Citations

This map shows the geographic impact of Roy van der Meel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy van der Meel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy van der Meel more than expected).

Fields of papers citing papers by Roy van der Meel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy van der Meel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy van der Meel. The network helps show where Roy van der Meel may publish in the future.

Co-authorship network of co-authors of Roy van der Meel

This figure shows the co-authorship network connecting the top 25 collaborators of Roy van der Meel. A scholar is included among the top collaborators of Roy van der Meel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy van der Meel. Roy van der Meel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Machine learning-guided high throughput nanoparticle design 2024 ·Digital Discovery ·(unknown), Derek van Tilborg, Roy van der Meel, Francesca Grisoni, Lorenzo Albertazzi	43
2	Lipid discovery for mRNA delivery guided by machine learning 2024 ·Nature Materials ·Roy van der Meel, Francesca Grisoni, Willem J. M. Mulder	13
3	Author Correction: Engineering cytokine therapeutics 2023 ·Nature Reviews Bioengineering ·Jeroen Deckers, (unknown), (unknown), Anne de Dreu, David P. Schrijver, (unknown), Yohana C. Toner, Thijs J. Beldman, Jamie B. Spangler, Tom F. A. de Greef, Francesca Grisoni, Roy van der Meel, Leo A. B. Joosten, Maarten Merkx, Mihai G. Netea, Willem J. M. Mulder	1
4	Engineering cytokine therapeutics breakdown → 2023 ·Nature Reviews Bioengineering ·Jeroen Deckers, (unknown), (unknown), Anne de Dreu, David P. Schrijver, (unknown), Yohana C. Toner, Thijs J. Beldman, Jamie B. Spangler, Tom F. A. de Greef, Francesca Grisoni, Roy van der Meel, Leo A. B. Joosten, Maarten Merkx, Mihai G. Netea, Willem J. M. Mulder	132
5	Author Correction: The current landscape of nucleic acid therapeutics 2021 ·Nature Nanotechnology ·Jayesh A. Kulkarni, Dominik Witzigmann, Sarah B. Thomson, Sam Chen, Blair R. Leavitt, Pieter R. Cullis, Roy van der Meel	16
6	The current landscape of nucleic acid therapeutics breakdown → 2021 ·Nature Nanotechnology ·Jayesh A. Kulkarni, Dominik Witzigmann, Sarah B. Thomson, Sam Chen, Blair R. Leavitt, Pieter R. Cullis, Roy van der Meel	934
7	Nanoengineering Apolipoprotein A1‐Based Immunotherapeutics 2021 ·Advanced Therapeutics ·David P. Schrijver, Anne de Dreu, (unknown), Ewelina Kluza, (unknown), Jeroen Deckers, (unknown), (unknown), (unknown), (unknown), (unknown), Rutger J. Röring, Thijs J. Beldman, Abraham J. P. Teunissen, Zahi A. Fayad, Roy van der Meel, Willem J. M. Mulder	11
8	Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery 2021 ·Small ·Roy van der Meel, Sam Chen, Josh Zaifman, Jayesh A. Kulkarni, (unknown), Ying K. Tam, Marcel B. Bally, Raymond M. Schiffelers, Marco A. Ciufolini, Pieter R. Cullis, Yuen Yi C. Tam	42
9	Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency 2020 ·Blood ·(unknown), Scott C. Meixner, Jerry Leung, (unknown), Jayesh A. Kulkarni, Hannah Russell, Roy van der Meel, Michael R. Sutherland, A. Phillip Owens, Joseph S. Palumbo, Edward M. Conway, Edward L.G. Pryzdial, Pieter R. Cullis, Christian J. Kastrup	25
10	Roadmap on nanomedicine 2020 ·Nanotechnology ·Paolo Decuzzi, Dan Peer, Daniele Di Mascolo, Anna Lisa Palange, Purnima Naresh Manghnani, S. Moein Moghimi, Z. Shadi Farhangrazi, Kenneth A. Howard, Daniel Rosenblum, Tingxizi Liang, Zhaowei Chen, Zejun Wang, Jun‐Jie Zhu, Zhen Gu, Netanel Korin, Didier Letourneur, Cédric Chauvierre, Roy van der Meel, Fabian Kießling, Twan Lammers	21
11	Dexamethasone nanomedicines for COVID-19 2020 ·Nature Nanotechnology ·Twan Lammers, Alexandros Marios Sofias, Roy van der Meel, Raymond M. Schiffelers, Gert Storm, Frank Tacke, Steffen Koschmieder, Tim H. Brümmendorf, Fabian Kießling, Josbert M. Metselaar	147
12	Smart cancer nanomedicine breakdown → 2019 ·Nature Nanotechnology ·Roy van der Meel, Einar Sulheim, Yang Shi, Fabian Kießling, Willem J. M. Mulder, Twan Lammers	946
13	The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs breakdown → 2019 ·Nature Nanotechnology ·Akin Akinc, Martin A. Maier, Muthiah Manoharan, Kevin Fitzgerald, Muthusamy Jayaraman, Scott Barros, Steven M. Ansell, Xinyao Du, Michael J. Hope, Thomas D. Madden, Barbara L. Mui, Sean C. Semple, Ying K. Tam, Marco A. Ciufolini, Dominik Witzigmann, Jayesh A. Kulkarni, Roy van der Meel, Pieter R. Cullis	1160
14	Translating nanomedicines: Thinking beyond materials? A young investigator's reply to ‘The Novelty Bubble’ 2018 ·Journal of Controlled Release ·Dominik Witzigmann, Sjoerd Hak, Roy van der Meel	11
15	PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time breakdown → 2016 ·Journal of Controlled Release ·Sander A. A. Kooijmans, Lies A. L. Fliervoet, Roy van der Meel, Marcel H.A.M. Fens, Harry F.G. Heijnen, Paul M.P. van Bergen en Henegouwen, Pieter Vader, Raymond M. Schiffelers	506
16	An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs 2015 ·European Journal of Pharmaceutical Sciences ·Lívia Neves Borgheti-Cardoso, Lívia Vieira Depieri, Sander A. A. Kooijmans, (unknown), (unknown), Fabiana T. M. C. Vicentini, Roy van der Meel, Márcia Carvalho de Abreu Fantini, Mamie Mizusaki Iyomasa, Raymond M. Schiffelers, Maria Vitória Lopes Badra Bentley	41
17	Capillary electrophoresis-based assessment of nanobody affinity and purity 2014 ·Analytica Chimica Acta ·Rob Haselberg, Sabrina Oliveira, Roy van der Meel, Govert W. Somsen, Gerhardus J. de Jong	14
18	Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells 2012 ·Journal of Controlled Release ·Işıl Altıntaş, Raimond Heukers, Roy van der Meel, M. Lacombe, Maryam Amidi, Paul M.P. van Bergen en Henegouwen, Wim E. Hennink, Raymond M. Schiffelers, Robbert J. Kok	97
19	Reprint of "Nanobody — Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting" 2011 ·Journal of Controlled Release ·Marina Talelli, Cristianne J.F. Rijcken, Sabrina Oliveira, Roy van der Meel, Paul M.P. van Bergen en Henegouwen, Twan Lammers, Cornelus F. van Nostrum, Gert Storm, Wim E. Hennink	28
20	Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach 2011 ·Angiogenesis ·Pieter Vader, Roy van der Meel, Marc Symons, Marcel H.A.M. Fens, (unknown), Karlijn J. Wilschut, G. Storm, Monika A. Jarzabek, William M. Gallagher, Raymond M. Schiffelers, Annette T. Byrne	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact